Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsekimig dose-ranging study in adults with moderate-to-severe asthma
CTR20240937Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of lunsekimig in asthma, sponsored by Sanofi. Started Mar 2024; status: completed.
02
Drugs
lunsekimig
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20240937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240937.